Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 2,200,000 shares, an increase of 1,169.5% from the January 31st total of 173,300 shares. Based on an average daily trading volume, of 5,000,000 shares, the short-interest ratio is currently 0.4 days. Currently, 54.6% of the company’s stock are short sold.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Maxim Group cut Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. StockNews.com began coverage on Moleculin Biotech in a research note on Tuesday. They issued a “sell” rating for the company.

Moleculin Biotech Stock Up 2.0 %

Shares of MBRX stock opened at $1.29 on Friday. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $10.35. The firm’s 50-day moving average is $1.55 and its 200-day moving average is $2.17.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.